Noyada (Captopril)

Captopril, the active ingredient in Noyada, is an ACE inhibitor presented as an oral tablet for oral use. It is used to manage hypertension, heart failure, and diabetic nephropathy in adult patients, helping to lower blood pressure and protect kidney function.

GNH USA supplies Noyada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from consistent product availability, comprehensive documentation, and responsive technical support.

Captopril is an ACE inhibitor that reduces activity of the renin‑angiotensin system, used in several cardiovascular and renal conditions.

- Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. - Heart failure: improves cardiac output and decreases symptoms of fluid overload. - Diabetic nephropathy: slows progression of kidney damage by lowering intraglomerular pressure.

Captopril may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Cough: persistent dry cough in some patients. - Taste disturbances: metallic or salty taste. - Dizziness or light‑headedness, especially after the first dose. - Fatigue or mild weakness. - Hypotension: noticeable drop in blood pressure. - Skin rash or itching.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that can compromise breathing. - Severe hyperkalemia: elevated potassium levels leading to cardiac arrhythmias. - Acute renal impairment: sudden decline in kidney function. - Neutropenia or agranulocytosis: marked reduction in white blood cells. - Hepatotoxicity: rare liver injury with jaundice. - Lupus‑like syndrome: systemic symptoms resembling lupus.

Before initiating therapy with Captopril, several safety considerations should be observed.

- Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte surveillance: monitor potassium levels to detect hyperkalaemia. - Pregnancy avoidance: contraindicated in pregnancy due to risk of fetal toxicity. - Cardiac status review: use cautiously in patients with aortic stenosis or recent myocardial infarction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Captopril can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use may cause severe hypotension and renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of dangerous hyperkalaemia. - Lithium: may raise lithium concentrations, leading to toxicity. - Dual ACE inhibitor/ARB therapy: heightens risk of renal impairment and hyperkalaemia. - NSAIDs (high‑dose): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood‑pressure lowering effect; monitor for hypotension. - Other antihypertensives: may require dose adjustments. - Trimethoprim‑sulfamethoxazole: can increase serum potassium. - Cyclosporine: may raise Captopril levels and affect renal function. - Diuretics causing volume depletion: monitor renal parameters and electrolytes.